• Regulatory NewsRegulatory News

    Second Major Sleep Drug Associated With Impaired Driving as FDA Dials Back Recommended Dosing

    The US Food and Drug Administration (FDA) has again issued a warning about a sleep drug, this time requiring a labeling change for the popular sleep drug Lunesta after data indicated that some patients experienced long-lasting effects that could impair their ability to function, even after a full night's sleep. Background Sleep drugs have long been on FDA's radar, primarily due to their association with impaired driving. The concern has been that some patients respond a...